Prostate‐specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low‐dose‐rate brachytherapy or external beam radiotherapy for localized prostate cancer

Prostate‐specific antigen nadir (nPSA) after radiotherapy for localized prostate cancer has been investigated as a predictor. However, nPSA usually requires several years, limiting its clinical utility. We investigated the significance of nPSA within 12 months (nPSA12) after low‐dose‐rate prostate b...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Nishimura, Shuichi, Ohashi, Toshio, Momma, Tetsuo, Sakayori, Masanori, Eriguchi, Takahisa, Tanaka, Tomoki, Yamashita, Shoji, Kosaka, Takeo, Oya, Mototsugu, Shigematsu, Naoyuki
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5943430/
https://ncbi.nlm.nih.gov/pubmed/29577651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1443
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars